ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 8, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the virtual Oppenheimer 33^rd Annual Healthcare Conference on Wednesday, March 15, 2023, at 11:20 a.m. Eastern Time.

David R. Parkinson, President and Chief Executive Officer of ESSA Pharma; Peter Virsik, ESSA's Chief Operating Officer; and David S. Wood, ESSA's Chief Financial Officer, will host and participate in one-on-one meetings.

A live webcast of the Oppenheimer presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days.

About ESSA Pharma Inc.

ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essapharma.com and follow us on Twitter under @ESSAPharma.

SOURCE ESSA Pharma Inc

Company Contact: Peter Virsik, Chief Operating Officer, ESSA Pharma Inc., Contact: [phone], Email: [email protected]; Investor Relations Contact: Xuan Yang, Managing Director, Solebury Strategic Communications, Contact: [phone], Email: [email protected]; Media Contact: Zara Lockshin, Vice President, Solebury Strategic Communications, Contact: [phone], Email: [email protected]